Found 386 oncology trials
A listing of oncology medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus
This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or …
A Phase II Study of the Anti-GITR Agonist INCAGN01876 and the PD-1 Inhibitor INCMGA00012 in Combination with Stereotactic Radiosurgery in Recurrent Glioblastoma
The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. …
Pilot Surgical PK Study of BGB324 in Recurrent Glioblastoma Patients
The purpose of this study is to test the ability of a new drug, BGB324, to get into the brain tumor (e.g.by crossing the blood brain barrier) in patients with recurrent glioblastoma who require surgery.
A Phase 1/2 Study of Oral LOXO-292 in Patients
LOXO-292 is a highly potent and specific inhibitor of the RET RTK, with minimal inhibition of other kinase and non-kinase targets, and therefore may be of benefit to patients with tumors (such as NSCLC, MTC, PTC, and colon or breast carcinomas) that harbor RET alterations and/or depend on RET activation. …
A Pilot Study of Risk-Guided Cardioprotection with Carvedilol in Breast Cancer Patients Treated with Doxorubicin and/or Trastuzumab
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, …
SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy After Second-line Hormonal Treatment
This is a research study for those with metastatic castration-resistant prostate cancer (mCRPC) that has progressed following treatment with prior therapy and cannot receive or refuse to receive chemotherapy. The purpose of this research study is to learn about the safety and effectiveness of 177Lu PNT2002, an investigational agent being …
Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
500 patients will be prospectively recruited to undergo a fast breast MRI examination. The women will be recruited for the study will meet the following criteria: 1. African American 2. negative DBT examination 11 months prior to recruitment 3. Heterogeneously and Extremely breast densities 4. clinically asymptomatic- no palpable masses, …
Comparing Drug abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)
The purpose of this study is to see if patients taking the study drug abelacimab have fewer bleeding events compared to those taking apixaban. Participation will last for about 8 months (6 months of treatment and 2 months of follow up). Participants may be paid up to a total of …
![IMAGING OF IN VIVO SIGMA-2 RECEPTOR EXPRESSION WITH [18F]ISO-1 POSITRON EMISSION TOMOGRAPHY (PET/CT) IN METASTATIC BREAST CANCER](/media/img/trial_thumbnails/PET-CT_Scanner_2_1okELH6.jpg)
IMAGING OF IN VIVO SIGMA-2 RECEPTOR EXPRESSION WITH [18F]ISO-1 POSITRON EMISSION TOMOGRAPHY (PET/CT) IN METASTATIC BREAST CANCER
Patients with metastatic breast cancer, that is biopsy proven or clinically documented by standard imaging (e.g. CT, MRI, Bone Scan, Ultrasound, FDG PET/CT), may be eligible for this study. Patients may participate in this study, if they are at least 18 years of age. We anticipate enrolling up to 30 …
Study of and Investigational drug in Participants with Advanced Renal Cell Carcinoma That Has Progressed
The research study is being conducted to evaluate the safety and effectiveness of MK-6482 when compared to treatment with everolimus for renal cell carcinoma.
Please choose between Voice or SMS based delivery of verification code
or